Grail, a company developing blood tests intended to detect cancer well before symptoms show, is taking its pitch to a broader swath of investors. The diagnostics company is looking ahead to potential commercialization of its technology as early as next year, and it has filed for an initial public offering to support its plans.
In paperwork filed with securities regulators Wednesday, the cancer diagnostics company set a preliminary $100 million target for its IPO. Menlo Park, CA-based Grail has applied for Nasdaq listing under the stock symbol “GRAL.”
Grail’s technology diagnoses cancer by detecting traces of genetic material that tumors shed... Read more »
UNDERWRITERS AND PARTNERS
Author: Frank Vinluan
Date : 2020-09-09T18:55:48.000Z